Advertisement

Common HIV Co-infections in China: HBV, HCV, and TB

  • Li LiEmail author
  • Jennifer M. McGoogan
  • Zunyou Wu
Chapter

Abstract

Co-infections common among people living with HIV (PLWH) in China include hepatitis B virus (HBV), hepatitis C virus (HCV), and Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB). On their own, each of these infectious diseases, HIV, HBV, HCV, and TB, are major contributors to the global burden of disease. In combination, they are clinically very challenging to manage and are generally associated with poorer outcomes including elevated morbidity and mortality. In China, PLWH, in general, bear a disproportionate burden of viral hepatitis and tuberculosis. However, people who acquired their HIV infection via injecting drug use are dramatically more vulnerable to HBV, HCV, and TB co-infection. China must endeavor to find these people with HIV co-infections, durably link them to care, and help them to initiate treatment. Enhanced screening and integrated care models would help China to better care for people with HIV co-infections.

References

  1. Akhtar A, Khan AH, Sulaiman SA, Soo CT, Khan K. HBV and HIV co-infection: prevalence and clinical outcomes in tertiary care hospital Malaysia. J Med Virol. 2016;88(3):455–60.  https://doi.org/10.1002/jmv.24347.CrossRefPubMedGoogle Scholar
  2. Askari A, Hakimi H, Nasiri Ahmadabadi B, Hassanshahi G, Kazemi Arababadi M. Prevalence of hepatitis B co-infection among HIV positive patients: narrative review article. Iran J Public Health. 2014;43(6):705–12.  https://doi.org/10.1016/j.ijid.2014.07.018.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat. 2016;23(7):545–59.  https://doi.org/10.1111/jvh.12519.CrossRefPubMedGoogle Scholar
  4. Chen X, He JM, Ding LS, Zhang GQ, Zou XB, Zheng J. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch Virol. 2013;158(9):1899–4.  https://doi.org/10.1007/s00705-013-1681-z.CrossRefGoogle Scholar
  5. Chen J, Cao W, Chen R, Ren Y, Li T. Prevalence and determinants of HIV in tuberculosis patients in Wuxi city, Jiangsu province, China: a cross-sectional study. Int J STD AIDS. 2016;27(13):1204–12.  https://doi.org/10.1177/0956462415612618.CrossRefPubMedGoogle Scholar
  6. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7–10.  https://doi.org/10.1111/jgh.12220.CrossRefPubMedGoogle Scholar
  7. Cui Z, Lin M, Nie S, Lan R. Risk factors associated with tuberculosis (TB) among people living with HIV/AIDS: a pair-matched case-control study in Guangxi, China. PLoS One. 2017;12(3):e0173976.  https://doi.org/10.1371/journal.pone.0173976.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Dong Y, Qiu C, Xia X, Wang J, Zhang H, Zhang X, et al. Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study. Arch Virol. 2015;160(4):929–36.  https://doi.org/10.1007/s00705-014-2311-0.CrossRefPubMedGoogle Scholar
  9. Gao L, Zhou F, Li X, Jin Q. HIV/TB co-infection in mainland China: a meta-analysis. PLoS One. 2010;5(5):e10736.  https://doi.org/10.1371/journal.pone.0010736.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Joint United Nations Programme on HIV/AIDS. Harm reduction programmes: saving lives among people who inject drugs. Geneva: Joint United Nations Programme on HIV/AIDS; 2017. http://www.unaids.org/en/resources/presscentre/featurestories/2017/june/20170621_harm_reduction. Accessed 12 Oct 2018.Google Scholar
  11. Joint United Nations Programme on HIV/AIDS. Global HIV and AIDS statistics—2018 fact sheet. Geneva: Joint United Nations Programme on HIV/AIDS; 2018. http://www.unaids.org/en/resources/fact-sheet. Accessed 1 Oct 2018.Google Scholar
  12. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356(14):1445–54.  https://doi.org/10.1056/NEJMra065142.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24(2):351–76.  https://doi.org/10.1128/CMR.00042-10.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Lai YJ, Liu EY, Wang LM, Morano JP, Wang N, Khoshnood K, et al. Human immunodeficiency virus infection-associated mortality during pulmonary tuberculosis treatment in six provinces of China. Biomed Environ Sci. 2015;28(6):421–8.  https://doi.org/10.3967/bes2015.059.CrossRefPubMedGoogle Scholar
  15. Liu Y, Zeng P, Wang J, Liu G, Xu M, Ke L, et al. Hepatitis B virus infection in a cohort of HIV infected blood donors and AIDS patients in Sichuan, China. J Transl Med. 2014;12:164.  https://doi.org/10.1186/1479-5876-12-164.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol. 2014;61(1):20–33.  https://doi.org/10.1016/j.jcv.2014.05.018.CrossRefPubMedGoogle Scholar
  17. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.  https://doi.org/10.1016/S0140-6736(11)61097-0.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Pisani E, Wu Z. HIV in China: 30 years in numbers. In: Wu Z, editor. HIV/AIDS in China—beyond the numbers. Singapore: People’s Medical Publishing House; 2017. p. 150–73.Google Scholar
  19. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.  https://doi.org/10.1016/S1473-3099(15)00485-5.CrossRefPubMedGoogle Scholar
  20. World Health Organization. Global hepatitis report 2015. Geneva: World Health Organization; 2015. http://apps.who.int/iris/bitstream/handle/10665/255017/WHO-HIV-2017.06-eng.pdf;jsessionid=99F2D433EE6208E3047CB4D156B88274?sequence=1. Accessed 12 Oct 2018.Google Scholar
  21. World Health Organization. Tuberculosis fact sheet. Geneva: World Health Organization; 2018a. http://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed 2 Oct 2018.Google Scholar
  22. World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018b. http://www.who.int/tb/publications/global_report/en/. Accessed 2 Oct 2018.Google Scholar
  23. Xu J, Tang W, Cheng S, Mahapatra T, Zhou L, Lai Y, et al. Prevalence and predictors of HIV among Chinese tuberculosis patients by provider-initiated HIV testing and counseling (PITC): a multisite study in South Central of China. PLoS One. 2014;9(2):e89723.  https://doi.org/10.1371/journal.pone.0089723.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Yan YX, Gao YQ, Sun X, Wang W, Huang XJ, Zhang T, et al. Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. Epidemiol Infect. 2011;139(3):354–60.  https://doi.org/10.1017/S0950268810001597.CrossRefPubMedGoogle Scholar
  25. Yan S, Chen L, Wu W, Fu Z, Zhang H, Li Z, et al. Early versus delayed antiretroviral therapy for HIV and tuberculosis co-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(5):e0127645.  https://doi.org/10.1371/journal.pone.0127645.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Yang R, Gui X, Xiong Y, Gao SC, Zhang Y. Interaction of hepatitis B and C viruses in patients infected with HIV. J Acquir Immune Defic Syndr. 2008;48(4):505–6.  https://doi.org/10.1097/QAI.0b013e31816de23c.CrossRefGoogle Scholar
  27. Yang R, Gui X, Xiong Y, Gao SC, Yan Y. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in a Chinese antiretroviral therapy center. Int J Infect Dis. 2014;28:29–34.  https://doi.org/10.1016/j.ijid.2014.07.018.CrossRefPubMedGoogle Scholar
  28. Yao T, Feng D, Pan M, Cheng Y, Li C, Wang J, et al. Related factors and interaction on HIV/HCV co-infection of patients access to methadone maintenance treatment. Chin J Epidemiol. 2018;39(5):631–5.  https://doi.org/10.3760/cma.j.issn.0254-6450.2018.05.017.CrossRefGoogle Scholar
  29. Zhang F, Zhu H, Wu Y, Dou Z, Zhang Y, Kleinman N, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study. Lancet Infect Dis. 2014;14(11):1065–72.  https://doi.org/10.1016/S1473-3099(14)70946-6.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Zhang C, Li X, Liu Y, Qiao S, Chen Y, Zhou Y, et al. Co-infections of tuberculosis, hepatitis B or C viruses in a cohort of people living with HIV/AIDS in China: predictors and sequelae. AIDS Care. 2017;29(8):974–7.  https://doi.org/10.1080/09540121.2016.1271388.CrossRefPubMedGoogle Scholar
  31. Zhou YH, Yao ZH, Liu FL, Li H, Jiang L, Zhu JW, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS One. 2012;7(8):e42937.  https://doi.org/10.1371/journal.pone.0042937.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.NCAIDSChina CDCBeijingChina

Personalised recommendations